20 Oct / 21
Absci Opens Door to New Biotechnology Campus
Vancouver, Washington headquarters expands company’s ability to accelerate discovery and development of next generation biologic drugs VANCOUVER, Wash., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and
14 Oct / 21
Absci to Report Third Quarter Financial Results on November 9, 2021
VANCOUVER, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced it will report financial results for the third quarter 2021
07 Sep / 21
Absci Reports Second Quarter 2021 Financial and Operating Results
VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30,
21 Jul / 21
Absci Announces Pricing of Initial Public Offering
VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering
14 Jun / 21
AbSci Announces Acquisition of Target Discovery Company Totient
- AbSci's approach to drug creation has the potential to disrupt conventional biologic drug discovery - Complementary technologies combined to enable streamlined design and production of next-generation therapeutic proteins for disease-specific targets VANCOUVER, Wash., June 14, 2021 /PRNewswire/
Displaying 1 - 10 of 14